Reviva To Present Negative Symptom Data For Brilaroxazine In Schizophrenia From Phase 3 Trials At CNS Summit 2025
RefinitivMeno di 1 minuto di lettura
Reviva Pharmaceuticals Holdings Inc 
RVPH:
REVIVA TO PRESENT NEGATIVE SYMPTOM DATA FOR BRILAROXAZINE IN SCHIZOPHRENIA FROM THE PHASE 3 RECOVER DOUBLE-BLIND AND OPEN-LABEL EXTENSION TRIALS AT THE CNS SUMMIT 2025
Accedi o crea un account gratuito per leggere queste notizie